Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication

Gene Therapy

Volumn 15, Issue 17, 2008, Pages 1240-1245

  Guedan, S ^a,b   Gros, A ^a   Cascallo, M ^a   Vile, R ^c   Mercade, E ^a   Alemany, R ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; RNA; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ADENOVIRUS; ARTICLE; CELL KILLING; CELL LYSATE; CELL NUCLEUS; CONTROLLED STUDY; CYTOTOXICITY; GENETIC TRANSFECTION; GIBBON LEUKEMIA VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNCYTIUM; TUMOR CELL; VIRUS GENOME; VIRUS REPLICATION;

CELL LINE, TUMOR; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GIANT CELLS; HUMANS; LEUKEMIA VIRUS, GIBBON APE; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS (GENETICS); TRANSGENES; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

ADENOVIRIDAE; GIBBON APE LEUKEMIA VIRUS;

EID: 50049100904     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.94     Document Type: Article

References (23)

1. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
2. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T et al Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 2000; 60: 6359-6366.
3. Vecil GG, Lang FF. Clinical trials of adenoviruses in brain tumors: A review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 2003; 65: 237-246.
4. Li H, Haviv YS, Derdeyn CA, Lam J, Coolidge C, Hunter E et al. Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. Hum Gene Ther 2001; 12: 2155-2165.
5. Sauthoff H, Pipiya T, Heitner S, Chen S, Norman RG, Rom WN et al. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther 2002; 13: 1859-1871.
6. Ahmed A, Jevremovic D, Suzuki K, Kottke T, Thompson J, Emery S et al Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Therapy 2003; 10: 1663-1671.
7. Cascante A, Abate-Daga D, Garcia-Rodriguez L, Gonzalez JR, Alemany R, Fillat C. GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model. Gene Therapy 2007; 14: 1471-1480.
8. Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res 2000; 60: 1492-1497.
9. Fielding AK, Chapel-Fernandes S, Chadwick MP, Bullough FJ, Cosset FL, Russell SJ. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther 2000; 11: 817-826.
10. Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ et al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 2002; 62: 6566-6578.
11. Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K et al Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 2002; 62: 5495-5504.
12. Fu X, Tao L, Jin A, Vile R, Brenner MK, Zhang X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003; 7: 748-754.
13. Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast Jr RC et al. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 2003; 9: 2727-2733.
14. Ebert O, Shinozaki K, Kournioti C, Park MS, Garcia-Sastre A, Woo SL. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 2004; 64 3265-3270.
15. Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Coffin RS. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 2006; 66: 4835-4842.
16. Gomez-Trevino A, Castel S, Lopez-Iglesias C, Cortadellas N, Comas-Riu J, Mercade E. Effects of adenovirus-mediated SV5 fusogenic glycoprotein expression on tumor cells. J Gene Med 2003; 5: 483-492.
17. Brade AM, Szmitko P, Ngo D, Liu FF, Klamut HJ. Heat-directed tumor cell fusion. Hum Gene Ther 2003; 14: 447-461.
18. Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ et al Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. J Gene Med 2004; 6: 1216-1227.
19. Garcia-Castro J, Martinez-Palacio J, Lillo R, Garcia-Sanchez F, Alemany R, Madero L et al. Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Ther 2005; 12 341-349.
20. Cascallo M, Alonso MM, Rojas JJ, Perez-Gimenez A, Fueyo J, Alemany R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther 2007; 15: 1607-1615.
21. Majem M, Cascallo M, Bayo-Puxan N, Mesia R, Germa JR, Alemany R. Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD. Cancer Gene Ther 2006, 13: 696-705.
22. Horn GP, Vongpunsawad S, Kornmann E, Fritz B, Dittmer DP, Cattaneo R et al. Enhanced cytotoxicity without internuclear spread of adenovirus upon cell fusion by measles virus glycoproteins. J Virol 2005; 79: 1911-1917.
23. Nadal M, Pera G, Pujadas J, Abril J, Gonzalez L, Aguilo F et al. Aneuploidy of chromosome Y in prostate tumors and seminal vesicles: A possible sign of aging rather than an indicator of carcinogenesis? Mol Carcinog 2007; 46: 543-552.